BG62383B1 - Метод за хормонзаместващо лечение - Google Patents

Метод за хормонзаместващо лечение Download PDF

Info

Publication number
BG62383B1
BG62383B1 BG99880A BG9988095A BG62383B1 BG 62383 B1 BG62383 B1 BG 62383B1 BG 99880 A BG99880 A BG 99880A BG 9988095 A BG9988095 A BG 9988095A BG 62383 B1 BG62383 B1 BG 62383B1
Authority
BG
Bulgaria
Prior art keywords
antiprogestin
estrogen
amount
administration
administered
Prior art date
Application number
BG99880A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG99880A (bg
Inventor
Gary D. Hodgen
Original Assignee
The Medical College Of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62383(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Medical College Of Hampton Roads filed Critical The Medical College Of Hampton Roads
Publication of BG99880A publication Critical patent/BG99880A/bg
Publication of BG62383B1 publication Critical patent/BG62383B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
BG99880A 1993-02-25 1995-08-23 Метод за хормонзаместващо лечение BG62383B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (2)

Publication Number Publication Date
BG99880A BG99880A (bg) 1996-02-28
BG62383B1 true BG62383B1 (bg) 1999-10-29

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99880A BG62383B1 (bg) 1993-02-25 1995-08-23 Метод за хормонзаместващо лечение

Country Status (25)

Country Link
US (1) US5468736A (pt)
EP (1) EP0686037B1 (pt)
JP (1) JP3441459B2 (pt)
KR (1) KR100248857B1 (pt)
AT (1) ATE202281T1 (pt)
AU (1) AU680239B2 (pt)
BG (1) BG62383B1 (pt)
BR (1) BR9406667A (pt)
CA (1) CA2157003C (pt)
CZ (1) CZ290562B6 (pt)
DE (1) DE69427529T2 (pt)
DK (1) DK0686037T3 (pt)
ES (1) ES2159552T3 (pt)
FI (1) FI953926A0 (pt)
GR (1) GR3036649T3 (pt)
HU (1) HU221169B1 (pt)
NO (1) NO309456B1 (pt)
NZ (1) NZ262657A (pt)
PL (1) PL176796B1 (pt)
PT (1) PT686037E (pt)
RO (1) RO115115B1 (pt)
RU (1) RU2139056C1 (pt)
SK (1) SK282921B6 (pt)
UA (1) UA43842C2 (pt)
WO (1) WO1994018983A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
CA2383659C (en) * 1999-08-31 2009-02-10 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
WO2002094276A1 (en) * 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
WO2002094278A1 (en) * 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
CA2448278C (en) * 2001-05-23 2010-06-08 Christian Franz Holinka Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ES2278925T3 (es) * 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
ES2274252T3 (es) * 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
ES2399423T3 (es) * 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
WO2004006936A1 (en) * 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ATE340580T1 (de) * 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
CA2673128C (en) * 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
EP2114412B1 (en) * 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
AU6245494A (en) 1994-09-14
BG99880A (bg) 1996-02-28
NO953243L (no) 1995-08-17
KR960700727A (ko) 1996-02-24
GR3036649T3 (en) 2001-12-31
FI953926A (fi) 1995-08-22
SK104995A3 (en) 1997-04-09
CZ204895A3 (en) 1996-03-13
RO115115B1 (ro) 1999-11-30
DE69427529T2 (de) 2001-11-22
SK282921B6 (sk) 2003-01-09
PT686037E (pt) 2001-09-28
US5468736A (en) 1995-11-21
BR9406667A (pt) 1996-01-23
RU2139056C1 (ru) 1999-10-10
FI953926A0 (fi) 1995-08-22
CA2157003C (en) 2001-04-17
ATE202281T1 (de) 2001-07-15
PL176796B1 (pl) 1999-07-30
HUT72080A (en) 1996-03-28
JP3441459B2 (ja) 2003-09-02
CA2157003A1 (en) 1994-09-01
DE69427529D1 (de) 2001-07-26
PL310660A1 (en) 1995-12-27
HU9502306D0 (en) 1995-09-28
UA43842C2 (uk) 2002-01-15
NZ262657A (en) 1997-05-26
KR100248857B1 (ko) 2000-04-01
NO309456B1 (no) 2001-02-05
CZ290562B6 (cs) 2002-08-14
EP0686037A4 (en) 1997-11-26
ES2159552T3 (es) 2001-10-16
DK0686037T3 (da) 2001-08-27
EP0686037A1 (en) 1995-12-13
WO1994018983A1 (en) 1994-09-01
HU221169B1 (en) 2002-08-28
AU680239B2 (en) 1997-07-24
JPH08510993A (ja) 1996-11-19
EP0686037B1 (en) 2001-06-20
NO953243D0 (no) 1995-08-17

Similar Documents

Publication Publication Date Title
BG62383B1 (bg) Метод за хормонзаместващо лечение
US5108995A (en) Hormone preparation and method
US5585370A (en) Hormone preparation and method
JP3208482B2 (ja) 避妊製剤
US5256421A (en) Hormone preparation and method
JP3937240B2 (ja) 黄体ホルモン関連の破綻出血の最小化
JPH0331213A (ja) 閉経後障害の治療
JPH10513152A (ja) 抗黄体ホルモンおよびプロゲスチンを含有する周期相ホルモン養生法
MXPA01009813A (es) Terapia interrumpida de reemplazo de hormonas con dosis bajas de estrogeno.
US7256185B1 (en) Control of selective estrogen receptor modulators
UA51627C2 (uk) Відновлення тонічної секреції естрогену з яєчників для довгочасних схем лікування
DK174181B1 (da) Farmaceutisk præparat til hormonbehandling
IE63453B1 (en) Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
IE84449B1 (en) Contraceptive packages containing oestrogen and progestin